Halozyme Therapeutics (NASDAQ:HALO) Downgraded by Zacks Research to Hold

Key Points

• Zacks Research has downgraded Halozyme Therapeutics from a "strong-buy" to a "hold" rating, reflecting a shift in sentiment among analysts regarding the stock's performance.
• Despite the downgrade, five analysts maintain a "buy" rating for Halozyme, while six rate it as "hold" and two issue a "sell" recommendation, indicating mixed opinions on the stock's future.
• In a recent earnings report, Halozyme Therapeutics exceeded expectations with a reported EPS of $1.54 and revenue of $325.72 million, marking a significant year-over-year revenue increase of 40.8%.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) was downgraded by equities researchers at Zacks Research from a "strong-buy" rating to a "hold" rating in a note issued to investors on Monday,Zacks.com reports. Zacks Research also issued estimates for Halozyme Therapeutics' Q1 2026 earnings at $1.00 EPS, Q2 2026 earnings at $1.28 EPS, Q3 2026 earnings at $1.49 EPS, FY2026 earnings at $5.75 EPS and Q2 2027 earnings at $1.48 EPS.

A number of other research firms have also recently weighed in on HALO. The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a "neutral" rating and a $55.00 target price on the stock. Wall Street Zen lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. JMP Securities lifted their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a research report on Wednesday, August 6th. Benchmark lifted their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Wednesday, September 24th. Finally, HC Wainwright raised their price objective on Halozyme Therapeutics from $85.00 to $90.00 and gave the company a "buy" rating in a research note on Thursday, October 2nd. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $70.44.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $66.02 on Monday. The firm has a 50-day moving average of $70.77 and a 200-day moving average of $61.97. The company has a market cap of $7.72 billion, a P/E ratio of 15.11, a P/E/G ratio of 0.36 and a beta of 1.16. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. Halozyme Therapeutics has a one year low of $42.01 and a one year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm's revenue for the quarter was up 40.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities research analysts forecast that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $69.03, for a total transaction of $1,380,600.00. Following the sale, the chief executive officer owned 733,719 shares in the company, valued at approximately $50,648,622.57. The trade was a 2.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Nicole Labrosse sold 2,227 shares of the business's stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $77.95, for a total transaction of $173,594.65. Following the sale, the chief financial officer owned 22,079 shares in the company, valued at approximately $1,721,058.05. This trade represents a 9.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 108,227 shares of company stock worth $7,779,595 over the last quarter. Corporate insiders own 2.90% of the company's stock.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds have recently bought and sold shares of the company. UMB Bank n.a. raised its position in Halozyme Therapeutics by 267.4% in the 1st quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company's stock worth $84,000 after buying an additional 960 shares during the last quarter. Park Avenue Securities LLC increased its position in shares of Halozyme Therapeutics by 10.9% during the 1st quarter. Park Avenue Securities LLC now owns 13,796 shares of the biopharmaceutical company's stock valued at $880,000 after purchasing an additional 1,357 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of Halozyme Therapeutics by 620.5% during the 1st quarter. Farther Finance Advisors LLC now owns 5,505 shares of the biopharmaceutical company's stock valued at $341,000 after purchasing an additional 4,741 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Halozyme Therapeutics by 199.0% during the 1st quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock valued at $179,000 after acquiring an additional 1,865 shares during the period. Finally, SG Americas Securities LLC grew its stake in shares of Halozyme Therapeutics by 117.1% during the 1st quarter. SG Americas Securities LLC now owns 26,841 shares of the biopharmaceutical company's stock valued at $1,713,000 after acquiring an additional 14,475 shares during the period. Institutional investors own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.